Evidence map›Paper›PMID 35605882›Full record

ArticleTransplantation and cellular therapy2022

Proceedings from the Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Immune and Cellular Therapy in Multiple Myeloma.

Sarah A Holstein, Fotis Asimakopoulos, Abdel Kareem Azab, Giada Bianchi, Manisha Bhutani, Leslie A Crews, Tom Cupedo, Hannah Giles, Sarah Gooding, Jens Hillengass and 13 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Transplantation and cellular therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 18 institutions in 4 countries.

Sarah A HolsteinUniversity of Nebraska Medical Center, Omaha, Nebraska. Electronic address: sarah.holstein@unmc.edu.
Fotis AsimakopoulosMoores Cancer Center, University of California San Diego, La Jolla, California.
Abdel Kareem AzabWashington University School of Medicine, St. Louis, Missouri.
Giada BianchiBrigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Manisha BhutaniLevine Cancer Institute, Charlotte, North Carolina.
Leslie A CrewsMoores Cancer Center, University of California San Diego, La Jolla, California.
Tom CupedoErasmusMC Cancer Institute Rotterdam, Rotterdam, The Netherlands.
Hannah GilesUniversity Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.
Sarah GoodingMRC Molecular Hematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.
Jens HillengassRoswell Park Comprehensive Cancer Center, Buffalo, New York.
Lukas JohnUniversity Hospital Heidelberg, Heidelberg, Germany.
Shari KaiserBristol Myers Squibb, Seattle, Washington.
Lydia LeeUniversity College London, London, United Kingdom.
Kylee MaclachlanMemorial Sloan Kettering Cancer Center, New York, New York.
Marcelo C PasquiniMedical College of Wisconsin, Milwaukee, Wisconsin.
Flavia PichiorriJudy and Bernard Briskin Center for Multiple Myeloma Research, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California; Department of Hematologic Malignancies Translational Science, Beckman Research Institute, City of Hope, Duarte, California.
Nina ShahUniversity of California San Francisco, San Francisco, California.
Monica ShokeenWashington University School of Medicine, St. Louis, Missouri.
Brian R ShyUniversity of California San Francisco, San Francisco, California.
Eric L SmithDana-Farber Cancer Institute, Boston, Massachusetts.
Raluca VeronaJanssen Research & Development, Spring House, Pennsylvania.
Saad Z UsmaniMemorial Sloan Kettering Cancer Center, New York, New York.
Philip L McCarthyRoswell Park Comprehensive Cancer Center, Buffalo, New York.
Memorial Sloan Kettering Cancer Center · USRoswell Park Comprehensive Cancer Center · USUniversity of California San Diego · USUniversity of California, San Francisco · USWashington University in St. Louis · USBrigham and Women's Hospital · USBristol-Myers Squibb (United States) · USCity of Hope · USDana-Farber Cancer Institute · USErasmus MC Cancer Institute · NLHeidelberg University · DEJanssen (United States) · USLevine Cancer Institute · USMedical College of Wisconsin · USNebraska Medical Center · USUniversity College London · GBUniversity Hospitals Birmingham NHS Foundation Trust · GBUniversity of Oxford · GB

Funding

Blood and Marrow Transplant Clinical Trials Network DCC- The Medical College of Wisconsin, Inc.U24HL138660 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI Steven M. DeVine, Mehdi Hussain Hamadani · 2017 to 2026
$71.4M
Easy-to-read Informed Consent for HCT Clinical TrialsU10HL069294 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI HOROWITZ, MARY MARESCA · 2011 to 2016
$43.8M
Exploring CD38 molecular biology and imaging in multiple myeloma pathogenesisR01CA248493 · NCI · WASHINGTON UNIVERSITY · PI SHOKEEN, MONICA · 2020 to 2024
$3.1M
Tumor matrix remodeling in anti-myeloma immunity and immunotherapyR01CA252937 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ASIMAKOPOULOS, FOTIOS · 2020 to 2024
$2.5M
Core transcriptional regulators of malignant stem cell generation in multiple myelomaR37CA252040 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Leslie A Crews · 2021 to 2026
$2.3M
MSKCC BMT CTN RenewalUG1HL069315 · NHLBI · SLOAN-KETTERING INST CAN RESEARCH · PI MIGUEL-ANGEL PERALES · 2017 to 2026
$2.2M
Functional Consequences of Ubiquitin Depletion During B Lymphocyte DifferentiationK08CA245100 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI BIANCHI, GIADA · 2020 to 2024
$1.0M
Medical Research Council MR/S001883/1NCI NIH HHS K08 CA245100NCI NIH HHS R01 CA248493NCI NIH HHS R01 CA252937NCI NIH HHS R37 CA252040NHLBI NIH HHS U10 HL069294NHLBI NIH HHS U24 HL138660NHLBI NIH HHS UG1 HL069315
6 · The paper itself

Abstract

The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup conducted a workshop on Immune and Cellular Therapy in Multiple Myeloma on January 7, 2022. This workshop included presentations by basic, translational, and clinical researchers with expertise in plasma cell dyscrasias. Four main topics were discussed: platforms for myeloma disease evaluation, insights into pathophysiology, therapeutic target and resistance mechanisms, and cellular therapy for multiple myeloma. Here we provide a comprehensive summary of these workshop presentations.

Indexed as

Multiple MyelomaBone MarrowCell- and Tissue-Based TherapyClinical Trials as TopicHumansCAR T cellImagingMultiple myelomaResistanceTumor microenvironment

Identifiers

PMID35605882
PMCPMC9357156
OpenAlexW4281260962

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.